# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹128 Cr** Q4 FY26 (+24%) · **₹478.5 Cr** FY26 * **EBITDA:** **₹25 Cr** Q4 FY26 (19.5% margin) · **₹90.1 Cr** FY26 (18.8% margin) * **PAT:** **₹14.7 Cr** Q4 FY26 (11.4% margin) · **₹42.2 Cr** FY26 (8.8% margin) * **Mature Hospital EBITDA Margin:** **23.06%** (Ex-Raipur) (+94 bps) ## B. Revenue & Margin Performance * **Portfolio Divergence:** Robust double-digit top-line growth across mature assets offset flat performance at the Dumdum facility, which underwent restructuring. * **Core Profitability Expansion:** Underlying margins for established hospitals showed healthy expansion of nearly **100 bps**, reflecting improved operational efficiency when excluding the Raipur ramp-up. ## C. Capital Allocation * **Investment Liquidation:** A corporate loan investment yielding a fixed coupon rate is slated for settlement within the **current financial year**, streamlining the balance sheet. --- # 2. Clinical & Specialty Performance ## A. Tertiary Care Mix & Market Trends * **Shift Toward Organized Care:** Increasing market preference for technology-led providers is driving demand across core specialties including cardiology, oncology, orthopedics, and neurology. * **Specialty Evolution at Agartala:** Current performance is anchored by cardiology and critical care, with oncology positioned as a primary future growth lever. ## B. Advanced Surgical Programs * **Robotic Surgery Leadership:** The Salt Lake facility has established itself as a high-volume center, completing over **800 robotic surgeries** annually. * **Strategic Expansion of High-Value Procedures:** Integration of 3D imaging and new cardiac surgery programs are enhancing tertiary capabilities across the network. * **Localized Growth Drivers:** ILS Howrah is leveraging its proximity to major transit hubs to scale its robotic knee replacement program, which completed nearly **100 procedures** in its first year. * **Facility-Specific Specialization:** Revenue at Raipur and Salt Lake is increasingly driven by high-end GI surgery, neurology, and interventional cardiology. * **Future Volume Projections:** Management expects to scale GI surgery volumes while diversifying the Dum Dum and Howrah facilities into cardiology and renal sciences. ## C. Oncology & Transplants * **Comprehensive Oncology Build-out:** ILS Agartala has transitioned to a full-service cancer center with the addition of PET scans and linear accelerator facilities. * **Transplant Program Momentum:** Renal transplant services have commenced in Tripura; management expects to commission **liver transplant** services in the near term to further differentiate the clinical mix. * **Niche Clinical Offerings:** Growth strategy includes the introduction of specialized services such as **cardiac electrophysiology** to capture underserved market segments. ## D. Diagnostic & Surgical Technology * **Technology Adoption:** Growth is being underpinned by the rapid adoption of robotic-assisted and minimally invasive surgeries, supported by rising insurance penetration. --- # 3. Hospital Operations & Capacity ## A. Key Figures * **Network Occupancy:** **45.87%** Overall (Impacted by new launches) * **Salt Lake (Flagship):** **63%** Occupancy · **₹43,800** Q4 ARPOB (+11.4%) · **3.06 Days** ALOS * **ILS Agartala:** **52%** Q4 Occupancy (vs. 42% YoY) · **18%** Operational Growth * **ILS Dum Dum:** **70%** Q4 Occupancy (vs. 65% YoY) * **Raipur (New):** **15%** Current Occupancy · **₹3.5 Cr** Revenue ## B. Occupancy Trends * **Flagship Performance:** Salt Lake and Dum Dum facilities have reached the **70% optimum occupancy mark**, with management targeting a mature ceiling of **72% to 73%** in the current fiscal. * **Regional Recovery:** Agartala is trending toward a **60%** target by next year, supported by a recovery in medical tourism from Bangladesh and an increase in visa request letters. * **New Launch Drag:** Overall network utilization remains suppressed by the Raipur facility, which is in its initial ramp-up phase (operational for **10.5 months**) and performing in line with internal expectations. * **Specialty Mix Accretion:** Growth across the network is being driven by higher patient throughput and a shift toward complex procedures, including dual-chamber leadless implantations and vascular stenting. ## C. Bed Capacity Expansion * **Future Pipeline:** Plans are underway to add **150 beds** via a new Jamshedpur facility slated for commissioning in **Q4 FY27**. * **Brownfield Potential:** While Kolkata hospitals are land-locked, the Agartala site holds vacant land capable of adding **100 additional beds** once utilization hits the **70%** threshold. * **Infrastructure Deficit:** Expansion strategy is underpinned by the significant domestic supply gap, with India’s bed density at **1.3 per 1,000 people** trailing global benchmarks. ## D. Facility Restructuring & Asset Utilization * **Strategic Turnaround:** The Dum Dum facility successfully re-strategized its delivery mix by decentralizing specialties, notably commissioning cardiac surgeries with **30 procedures** completed in a single quarter. * **Operational Efficiency:** Management is prioritizing interventional radiology and neurology to optimize asset utilization and drive a projected **10%** growth rate at restructured units. * **Data Reconciliation:** Note a minor discrepancy between management's verbal occupancy figures for Salt Lake (**67-68%**) versus the formal presentation (**62.4%**), currently pending internal verification. --- # 4. Patient & Payer Metrics ## A. Key Figures * **ARPOB:** **₹39,200** Network Average (+5.9%) · **~₹35,000** Jamshedpur Target · **~₹35,000** Raipur Current * **Payer Mix:** **90%** Cash & Insurance (50/50 split) · **10%** Corporate & Schemes * ALOS: 4.47 Days Network Average (vs. 4.59) · 3 Days Salt Lake (vs. late 3s) ## B. ARPOB & Occupancy Trends * **Growth Outlook:** Management projects high single-digit ARPOB expansion for FY27, fueled by tariff hikes and a shift toward higher-acuity specialty cases. * **Strategic Discounting:** Agartala unit maintains lower realizations due to intentional affordability-linked pricing, though annual growth of **7% to 8%** is expected as the facility matures. * **Yield Normalization:** Anticipated empanelment with corporates and insurers may lead to a **4% to 5%** tactical reduction in ARPOB as the payer base diversifies away from pure cash. * **Efficiency Gains:** Significant reduction in length of stay, particularly at Salt Lake, is successfully unlocking capacity and driving higher throughput. ## C. Payer Mix & Market Positioning * **High-Quality Revenue:** A dominant contribution from cash and insurance segments underscores a robust tertiary care profile and strong collection visibility. * **Raipur Performance:** Initial ARPOB at the new Raipur facility is tracking in line with mature West Bengal units, currently buoyed by a predominantly cash-paying patient base. * **Scheme Exposure:** Minimal reliance on government schemes like Ayushman Bharat, which currently represent only **~5%** of the total revenue mix. --- # 5. Expansion & Strategic Initiatives ## A. Key Figures * **Raipur Occupancy:** **14%** Current · **30%** Target by Q4 * **Raipur Financial Impact:** **-₹13.8 Cr** EBITDA · **₹12.8 Cr** Addl. Depreciation & Finance Costs * **Raipur Breakeven Target:** **Q3 FY26** Est. Monthly Operational Breakeven (at **~25%** occupancy) * **Jamshedpur Capacity:** **150 beds** Planned tertiary care * **Regional Bed Density:** **1.15 beds per 1,000** Raipur/Chhattisgarh market ## B. New Facility Ramp-up * **Accelerated Breakeven Trajectory:** Management expects the Raipur facility to achieve monthly operational breakeven by Q3, significantly outperforming the standard **24 to 36-month** industry cycle. * **Clinical Milestones:** The Raipur unit has already secured liver transplant licenses and operationalized comprehensive oncology services, driving early traction in high-end tertiary care. * **Infrastructure Advantage:** Occupancy growth is supported by a strategic city-center location and premium technology, including a **3 Tesla MRI**, providing a first-mover advantage over local incumbents. * **Future Pipeline Scaling:** The Jamshedpur project is tracking on schedule with an anticipated first-year occupancy ramp-up mirroring the Raipur trajectory. ## C. M&A Pipeline & Regional Strategy * **Strategic Expansion Goal:** The company is executing a disciplined capital allocation strategy to reach a **1,000-bed** chain capacity, focusing on underserved Central and Eastern Indian corridors. * **M&A Target Profile:** Active evaluation is underway for acquisitions in Eastern India, specifically targeting high-quality assets with a sweet spot of **150 to 200 beds**. * **Market Fundamentals:** Growth is underpinned by a severe shortage of tertiary infrastructure in the East, coupled with rising insurance penetration and a shift toward lifestyle disease treatment. --- # 6. Risks & Healthcare Externalities ## A. Key Figures * **Agartala Patient Mix (Bangladesh):** **3%** current contribution (vs. **10%** historical) * **Raipur Empanelment Timeline:** **15-month** delay; completion expected **next quarter** ## B. Operational & Geopolitical Risks * **Cross-Border Volatility:** Revenue from Bangladeshi patients at Agartala has seen a significant contraction, though rising visa requests signal a return to historical double-digit levels. * **Regional Disruptions:** Footfalls saw a temporary dip due to the **Bengal elections** in late FY26 and early Q1 FY27, though the annualized impact remains negligible. * **Execution Headwinds:** The Raipur facility ramp-up has been hampered by prolonged insurance empanelment delays, with a resolution anticipated in the near term to unlock financial performance. ## C. Human Capital & Regulatory Outlook * **Staffing Resilience:** Management is mitigating industry-wide nursing attrition by leveraging an established clinical foundation to maintain core team stability against new market entrants. * **Regulatory Neutrality:** The anticipated transition from **Swasthya Sathi** to **Ayushman Bharat** in West Bengal is projected to be revenue-neutral, with no expected impact on ARPOB or scheme volumes. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth:** **15%** YoY for FY26 & FY27 (incl. Raipur) * **EBITDA Margin:** **20.2%** target (+100 bps YoY) * **ARPOB Growth:** **7% to 8%** projected for FY27 * **Occupancy Targets (FY27):** **70%** Salt Lake · **72-73%** Dum Dum · **58%** Agartala · **~30%** Raipur * **Capex Intensity:** **₹70 Lakhs** per bed (Jamshedpur) ## B. Revenue & Profitability Drivers * **Top-line Momentum:** Sustained double-digit revenue growth expected through FY27, supported by the integration of the Raipur facility. * **Yield Optimization:** ARPOB expansion to be fueled by strategic tariff adjustments and departmental mix optimization. * **Profitability Timeline:** Management anticipates Raipur will reach break-even in FY27, though Jamshedpur is expected to remain in a loss-making phase initially. ## C. Margin & Operational Efficiency * **Margin Accretion:** Projected triple-digit basis point improvement in EBITDA margins as higher occupancy in mature units offsets gestation losses from new facilities. * **Howrah Turnaround:** Productivity gains from a revised specialty mix and technology upgrades are expected to push Howrah occupancy toward **60%** by Q1 FY26. ## D. Capex & Expansion Timeline * **Deployment Schedule:** Capital expenditure for Jamshedpur is front-loaded, with **90%** of spend occurring in the current fiscal year. * **Investment Benchmarking:** Capital intensity for the Jamshedpur expansion remains disciplined, aligning with the investment parity established at the Raipur site.